---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-003610"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2022-03-15T23:59:59+00:00"
generated_at: "2026-06-26T22:40:13.476226+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports Q4 2021 net loss of $23.9M ($0.57/share); cash $190.3M; pemvidutide trials on track

## Summary
- Net loss $23.9M ($0.57 per share) vs $10.6M ($0.29) in Q4 2020; R&D expense doubled to $20.2M on pemvidutide development.
- Cash, equivalents and short-term investments of $190.3M at Dec 31, 2021; revenue $3.3M vs $2.3M.
- Pemvidutide Phase 1b NAFLD trial >90% enrolled; topline data expected Q3 2022.
- Phase 2 MOMENTUM obesity trial (48 wks) initiation expected Q1 2022; interim data at 24 wks in Q4 2022.
- HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; readout expected H1 2023.

## SEC filing metadata
- accession: 0001558370-22-003610
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2022-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000155837022003610/0001558370-22-003610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000155837022003610/alt-20220315x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-003610
- JSON: https://secwatch.observer/filing/0001558370-22-003610.json
- Plain text: https://secwatch.observer/filing/0001558370-22-003610.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.